A trial of antidepressant therapy to improve COVID-19 outcomes In December of 2020,Lenze and colleaguespublishedthe results of their randomized trial…

Question A trial of antidepressant therapy to improve COVID-19 outcomes In December of 2020, Lenze and colleagues published the results of their randomized trialActionsof an antidepressant drug (fluvoxamine, brand name Lovax) for COVID-19 outcome improvement. The purpose of the trial was to test the hypothesis that therapy with this specific antidepressant, a type of a selective serotonin reuptake inhibitor (SSRI), can help patients with mild COVID-19 avoid clinical deterioration, thus resulting in milder disease severity. The questions below are based on material from the published article. Note that not all questions will have an unequivocally right answer, and we are primarily looking for a thoughtful, well supported answer.  A. Was the study blinded? If so, was it single-, double-, or triple-blinded? Describe the implications of blinding for the validity of these findings. B. The purpose of randomization was to try to balance the baseline characteristics evenly across the experimental group and control group, so that the groups would be comparable. Of the variables listed in the Table 1, are there any that have been poorly balanced? How would these imbalances, if any, impact the interpretation of the findings? Please justify your answers. C. The following information was given about the possible effect of fluvoxamine: “Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 (8.3%) patients in the placebo group.”Using the numbers given above, calculate the efficacy of fluvoxamine for preventing clinical deterioration. Please show your calculations.D. What happens when you calculate number needed to treat (NNT) to avoid one case of clinical deterioration? Use the numbers in part C to explore that question.E. The ultimate objective of a randomized trial is to generalize the results beyond the study population itself. Such generalizability is enhanced for populations that are similar to the study population. Based on the trial inclusion criteria given in the article (the Participants section on pages 2293-2294 and Figure 1), how well do you think the results would generalize to the following groups of individuals? Please provide explanations for your answers.Individuals who live outside of the area of recruitment (St Louis).Participants who dropped out of the study (pages 2296-2298, Missing Data)Individuals with a severe COVID-19 disease course.Individuals who are already taking fluvoxamine for depression/anxiety. Health Science Science Nursing EPID 765 Share QuestionEmailCopy link Comments (0)